Biogen has not given up on early access for Aduhelm

28 January 2022
biotech_infusion_hospital_big

US Food and Drug Administration approval may have felt like the finishing line, but a long and winding road to reimbursement still stretches ahead for Aduhelm (aducanumab).

With Medicare  refusing to offer the novel Alzheimer’s med outside of the clinical trial setting, data from confirmatory studies could be critical to its future prospects.

Developers Biogen (Nasdaq: BIIB) and Eisai (TYO: 4523) have now released details of their plans for Phase IV research, designed to convert their US FDA Accelerated Approval into regular authorization.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK

Companies featured in this story

More ones to watch >


Today's issue

Company Spotlight





More Features in Biotechnology